Tobacco and nicotine use psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
3 registered studies are counted for tobacco and nicotine use. By compound: 3 psilocybin. By registry status: 1 recruiting, 1 not yet recruiting and 1 completed. By phase: 2 phase 2 and 1 not applicable. Reported start years run from 2008 (earliest) to 2027 (latest).
Studies are matched when the title names smoking cessation, tobacco use or nicotine dependence. Studies of nicotinic receptors are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 3 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 33% |
| Not yet recruiting | 1 | 33% |
| Completed | 1 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 2 | 67% |
| Not applicable | 1 | 33% |
Countries
Country is taken from the study's linked research site. 1 of 3 records have no country on file. The top 1 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 2 | 67% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 1 |
| 2020 to 2023 | 1 |
| Before 2010 | 1 |
Study design
- 3 interventional and 0 observational studies.
- Median planned or actual enrolment is 66 participants (range 3 to 82, across 3 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Effects of Psilocybin on Craving in Nicotine Dependence | NCT07852832 | Not yet recruiting | Phase 2 | 2027-01-01 | Psilocybin |
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | NCT05452772 | Recruiting | Phase 2 | 2023-11-01 | Psilocybin |
| Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study | NCT01943994 | Completed | Not applicable | 2008-09-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk